EDITORIALS |

Department of Psychiatry, University of Manchester, Manchester M13 9PL, UK. Email: alistair.burns{at}manchester.ac.uk
A.B. has received research funding, honoraria and expenses for consultancy work from companies involved in the manufacturing and marketing of drugs for dementia: Baxter, Eisai, Janssen, Lundbeck, Novartis, Pfizer and Shire.
Alistair Burns (pictured) is Professor of Old Age Psychiatry at the University of Manchester and an Honorary Consultant Psychiatrist in the Manchester Mental Health and Social Care Trust.
See pp.
212–219, this
issue.
An emerging appreciation by practitioners and researchers, long held by patients and carers, is that neuropsychiatric features of dementia and the challenges they present are as important as those of cognitive losses.
Related articles in BJP:
Read all eLetters